Free Trial

Penumbra (PEN) Competitors

Penumbra logo
$265.19 +0.45 (+0.17%)
Closing price 03:59 PM Eastern
Extended Trading
$264.17 -1.02 (-0.39%)
As of 05:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PEN vs. LNTH, ITGR, GEHC, PHG, ZBH, SNN, SOLV, STVN, GKOS, and BLCO

Should you be buying Penumbra stock or one of its competitors? The main competitors of Penumbra include Lantheus (LNTH), Integer (ITGR), GE HealthCare Technologies (GEHC), Koninklijke Philips (PHG), Zimmer Biomet (ZBH), Smith & Nephew SNATS (SNN), Solventum (SOLV), Stevanato Group (STVN), Glaukos (GKOS), and Bausch + Lomb (BLCO). These companies are all part of the "medical" sector.

Penumbra vs. Its Competitors

Penumbra (NYSE:PEN) and Lantheus (NASDAQ:LNTH) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

88.9% of Penumbra shares are held by institutional investors. Comparatively, 99.1% of Lantheus shares are held by institutional investors. 5.0% of Penumbra shares are held by insiders. Comparatively, 2.0% of Lantheus shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Penumbra currently has a consensus price target of $300.47, suggesting a potential upside of 13.30%. Lantheus has a consensus price target of $105.50, suggesting a potential upside of 87.86%. Given Lantheus' higher probable upside, analysts clearly believe Lantheus is more favorable than Penumbra.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Penumbra
0 Sell rating(s)
3 Hold rating(s)
13 Buy rating(s)
2 Strong Buy rating(s)
2.94
Lantheus
0 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.71

Lantheus has a net margin of 17.82% compared to Penumbra's net margin of 11.54%. Lantheus' return on equity of 34.06% beat Penumbra's return on equity.

Company Net Margins Return on Equity Return on Assets
Penumbra11.54% 11.55% 8.76%
Lantheus 17.82%34.06%19.10%

In the previous week, Lantheus had 18 more articles in the media than Penumbra. MarketBeat recorded 29 mentions for Lantheus and 11 mentions for Penumbra. Penumbra's average media sentiment score of 1.06 beat Lantheus' score of 0.64 indicating that Penumbra is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Penumbra
7 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Lantheus
12 Very Positive mention(s)
4 Positive mention(s)
8 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Penumbra has a beta of 0.4, suggesting that its share price is 60% less volatile than the S&P 500. Comparatively, Lantheus has a beta of 0.14, suggesting that its share price is 86% less volatile than the S&P 500.

Lantheus has higher revenue and earnings than Penumbra. Lantheus is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Penumbra$1.19B8.66$14.01M$3.7670.53
Lantheus$1.53B2.49$312.44M$3.7614.94

Summary

Penumbra and Lantheus tied by winning 8 of the 16 factors compared between the two stocks.

Get Penumbra News Delivered to You Automatically

Sign up to receive the latest news and ratings for PEN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PEN vs. The Competition

MetricPenumbraMED INSTRUMENTS IndustryMedical SectorNYSE Exchange
Market Cap$10.32B$6.92B$5.76B$21.10B
Dividend YieldN/A1.30%4.40%3.55%
P/E Ratio75.4226.9130.1928.89
Price / Sales8.66148.25474.9853.02
Price / Cash91.7122.3525.7818.23
Price / Book8.844.859.424.69
Net Income$14.01M$176.42M$3.27B$995.89M
7 Day Performance3.85%-0.15%2.05%1.90%
1 Month Performance13.73%-2.91%3.58%1.72%
1 Year Performance26.21%8.70%30.09%10.19%

Penumbra Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PEN
Penumbra
4.7557 of 5 stars
$265.19
+0.2%
$300.47
+13.3%
+26.0%$10.32B$1.19B75.424,500Positive News
Insider Trade
LNTH
Lantheus
4.7519 of 5 stars
$55.97
+3.3%
$105.50
+88.5%
-45.7%$3.81B$1.53B14.89700News Coverage
Analyst Revision
ITGR
Integer
3.925 of 5 stars
$105.61
-1.1%
$140.25
+32.8%
-12.7%$3.70B$1.72B46.5211,000Positive News
GEHC
GE HealthCare Technologies
3.5326 of 5 stars
$73.17
-0.3%
$88.55
+21.0%
-11.3%$33.41B$19.67B14.9953,000Positive News
PHG
Koninklijke Philips
4.0047 of 5 stars
$27.47
flat
N/A-6.1%$26.45B$19.50B144.5866,678News Coverage
Positive News
ZBH
Zimmer Biomet
4.7419 of 5 stars
$102.67
-0.1%
$111.44
+8.5%
-6.5%$20.34B$7.68B24.9817,000Positive News
SNN
Smith & Nephew SNATS
3.1602 of 5 stars
$36.29
+0.2%
$36.00
-0.8%
+21.5%$15.89B$5.81B16.8017,349News Coverage
Positive News
Analyst Downgrade
SOLV
Solventum
1.6739 of 5 stars
$70.87
-0.8%
$85.75
+21.0%
+19.6%$12.29B$8.25B32.8122,000Positive News
Analyst Downgrade
STVN
Stevanato Group
N/A€22.50
-0.5%
N/A+21.1%€6.81B€1.19B41.675,521Positive News
GKOS
Glaukos
4.715 of 5 stars
$89.47
-0.4%
$127.42
+42.4%
-29.1%$5.13B$432.95M-54.22780Positive News
Analyst Revision
BLCO
Bausch + Lomb
1.6203 of 5 stars
$14.49
-0.4%
$15.56
+7.4%
-8.3%$5.13B$4.79B-18.5713,500

Related Companies and Tools


This page (NYSE:PEN) was last updated on 8/25/2025 by MarketBeat.com Staff
From Our Partners